IRCT2016081329326N1 IRCT 2016-09-11 Tehran University of Medical Sciences Effect of Latanaprost eye drop on retina after cataract surgery in glaucoma patients Effect of continuation of prostaglandin analogue use on the incidence of Cystoid Macular Edema (CME) following uncomplicated cataract surgery in glaucoma patients 2016-09-21 anticipated 166 Complete https://irct.ir/trial/23602 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: A computer-based program (Excel® Microsoft Office software version 2016) to assign our samples to the two groups was used. The randomization used was block permutated randomization with the random block size of 2,4 and 6. The random sequence obtained by a biostatistician and it was concealed from the research group by coloring the background of cells in Excel datasheet. Whenever each new patient was a candidate for allocation, one author (M.M) uncolored the devoted cell and allocated the patient according to the written number, 1 for continuing and 2 for stop continuing latanoprost, Blinding description: The design of the RCT was single-masked. Patients were aware of the allocation, while surgeon/examiner (GH.F.), outcome assessor/analyst (M.Y.) were masked to the patient allocation which was done by M.M. 2 Cystoid macular edema. Intervention 1: Intervention group : In this group, prostaglandin analogue (Latanaprost eye drop) is discontinued immediately after cataract surgery for 3 months and replaced with other antiglaucoma agents to control IOP. Intervention 2: Control group: Prostaglandin analogue (Latanaprost eye drop, one drop before sleep at night) after cataract surgery will be continued. https://www.jcrsjournal.org/article/S0886-3350(19)30428-6/abstract Purpose To evaluate the effect of postoperative latanoprost administration on central macular thickness (CMT) after uneventful cataract surgery in glaucoma patients. Setting Farabi Eye Hospital, Tehran, Iran. Design Prospective randomized clinical trial. Methods In this single-masked trial, glaucoma patients treated with latanoprost who had no other risk factor for the development of pseudophakic macular edema were randomly allocated to continuation of latanoprost or discontinuation of the drop after uneventful cataract surgery. At baseline and postoperatively at 1 month and 3 months, patients had complete ocular examinations and CMT measurements using optical coherence tomography. The main outcome measure was the change in the CMT between baseline measurements and postoperative measurements at 1 month and 3 months. Results One hundred fifty-six eyes (latanoprost 76; discontinuation 80) finished the trial. There were no differences in baseline patient demographics or characteristics, including the CMT, between the two groups. There was transient increase in the mean CMT by 12 μm ± 49 (SD) in the latanoprost group at 1 month (P = .03); however, the value returned to baseline by 3 months (6 ± 55 μm; P = .27). The between-group difference in the mean change in the CMT from baseline was −3.1 μm (95% confidence interval [CI], −18.4 to 12.0; P = .68) after 1 month and −10.5 μm (95% CI, −26.6 to 5.5; P = .19) after 3 months; the differences were not significant. Conclusion Latanoprost administration after cataract surgery had no measurable effect on macular thickness. No - There is not a plan to make this available Justification or reason for not sharing IPD is Not published due to Farabi Eye Research department guidelines.